News
11 December 2024
Conditions like dementia and Alzheimer’s disease have the most likelihood of a medical breakthrough in the next 10 years. However, at present, there are few effective treatment options. For ASX-listed Neuroscientific Biopharmaceuticals (NSB), this is a focus area that shows great commercial promise and opportunity to improve patient outcomes.
Conditions like dementia and Alzheimer’s disease have the most likelihood of a medical breakthrough in the next 10 years. However, at present, there are few effective treatment options. For ASX-listed Neuroscientific Biopharmaceuticals (NSB), this is a focus area that shows great commercial promise and opportunity to improve patient outcomes.
Neuroscientific Biopharmaceuticals (NSB) is developing EmtinB, a drug in advanced preclinical studies that is showing promise in treating degenerative conditions such as Alzheimer’s disease. EmtinB has slowed the progression of Alzheimer’s by more than 80% in animal subjects.
EmtinB has also shown promise as a treatment for degenerative conditions of the optic nerve, such as caused by glaucoma. In one trial, the drug enabled severed optic nerves to almost fully grow back.
The drug was also used to treat optic degeneration caused by glaucoma in pig models that closely resemble severe human form of glaucoma.
“We were able to stop that degeneration,” says NSB’s CEO and MD, Matt Liddelow.
It may potentially also be used to treat spinal cord injuries and multiple sclerosis (MS).
At the moment, the drug is administered by subcutaneous or intravitreal injection, although NSB is currently looking at less invasive delivery methods for ocular indications such as eye drops.
“We’re focused on getting EmtinB preclinical safety studies completed so we can start clinical studies by the end of the year,” says Liddelow. “Nothing we’ve seen so far has indicated we’re going to have any major safety problems in clinical studies.”
To streamline the process, NSB is partnered with some of the best pharmaceutical research and manufacturing organisations on the planet. This includes Covance, a US company that had handlings in the clinical trials of 50 of the top drugs now in the market.
“We’ve got a healthy cash position of around $4m in the bank. That’s more than enough to get us to achieve what we need to do in the next 12 months,” says Matt.
Watch the video to learn more about NSB from MD and CEO, Matt Liddelow.
Join next week’s ‘Meet The CEOs’ webcast – Click here to book your spot.
Recorded on 10 June 2020 at 12pm.
